reports
RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical ...
TOKYO--(BUSINESS WIRE)-- , a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (TOKYO:4591), today announced that the first subject in cohort 1 was administered with RBM-007 subcutaneously in Phase 1 clinical trial in Japan. This represents the second indication for the innovative molecule, which is currently under phase 2 trial in the United States for the treatment of age-related macular degeneration. About RBM-007 RBM-007 is a novel nucleic acid medicine (oligonucleotide-based aptamer) developed in-hou...
RIBOMIC Enters License Agreement with AJU Pharma for RBM-007 in Age-re...
TOKYO--(BUSINESS WIRE)-- , a clinical stage pharmaceutical company specializing in aptamer therapeutics (“RIBOMIC” TSE-Mothers : 4591, President and CEO : Yoshikazu Nakamura, Ph.D.) today announced that RIBOMIC has signed the license agreement with AJU PHARM CO., LTD., Korean pharmaceutical company (“AJU”), for RBM-007 licensing agreement for the indication of the exudative age-related macular degeneration in the territory of Korea and Southeast Asia (Singapore, Philippines, Thailand, Vietnam, Indonesia, Malaysia, Cambodia and Myanmar; hereinafter "the Territory"). Upon execution of this Agree...
RIBOMIC annonce la première injection dans l’essai clinique de phas...
TOKYO--(BUSINESS WIRE)-- RIBOMIC, Inc., une société pharmaceutique de stade clinique, spécialisée dans les produits thérapeutiques à base d’aptamères, et cotée au Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui qu’un premier patient avait reçu une injection de RBM-007 dans le cadre de l’essai de phase 2 portant sur le RBM-007, pour le traitement de la dégénérescence maculaire liée à l’âge (DMLA) exsudative, aux États-Unis. Le premier site a commencé le recrutement des patients fin décembre 2019, et cinq sites sont désormais actifs à travers les États-Unis. ...
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM...
TOKYO--(BUSINESS WIRE)-- RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States. About RBM-007 and development background RBM-007 is a novel oligonucleotide-based aptamer with po...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.